Prometheus Biosciences, Inc., (RXDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RXDX Stock Summary
- With a price/sales ratio of 749.01, PROMETHEUS BIOSCIENCES INC has a higher such ratio than 99.38% of stocks in our set.
- As for revenue growth, note that RXDX's revenue has grown 117.61% over the past 12 months; that beats the revenue growth of 94.07% of US companies in our set.
- In terms of volatility of its share price, RXDX is more volatile than 93.47% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to PROMETHEUS BIOSCIENCES INC are KRTX, XENE, RAPT, KDNY, and MRUS.
- RXDX's SEC filings can be seen here. And to visit PROMETHEUS BIOSCIENCES INC's official web site, go to www.prometheusbiosciences.com.
RXDX Valuation Summary
- In comparison to the median Healthcare stock, RXDX's price/sales ratio is 15836.17% higher, now standing at 749.
- Over the past 25 months, RXDX's price/sales ratio has gone up 2.9.
Below are key valuation metrics over time for RXDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RXDX | 2023-03-24 | 749.0 | 7.5 | -36.0 | -34.1 |
| RXDX | 2023-03-23 | 746.7 | 7.5 | -35.9 | -34.0 |
| RXDX | 2023-03-22 | 743.2 | 7.5 | -35.7 | -33.8 |
| RXDX | 2023-03-21 | 787.1 | 7.9 | -37.8 | -36.0 |
| RXDX | 2023-03-20 | 803.0 | 8.1 | -38.6 | -36.7 |
| RXDX | 2023-03-17 | 786.2 | 7.9 | -37.8 | -35.9 |
RXDX Price Target
For more insight on analysts targets of RXDX, see our RXDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $34.67 | Average Broker Recommendation | 1.12 (Strong Buy) |
RXDX Stock Price Chart Interactive Chart >
RXDX Price/Volume Stats
| Current price | $111.29 | 52-week high | $129.60 |
| Prev. close | $109.68 | 52-week low | $21.50 |
| Day low | $107.75 | Volume | 311,400 |
| Day high | $112.21 | Avg. volume | 511,252 |
| 50-day MA | $116.17 | Dividend yield | N/A |
| 200-day MA | $71.41 | Market Cap | 5.29B |
Prometheus Biosciences, Inc., (RXDX) Company Bio
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Latest RXDX News From Around the Web
Below are the latest news stories about PROMETHEUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RXDX as an investment opportunity.
Prometheus Biosciences' (NASDAQ:RXDX) investors will be pleased with their stellar 170% return over the last yearUnfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really... |
Positive Clinical Trial Results Pushed Prometheus Biosciences (RXDX) in Q4Alger Capital, an investment management company, released its “Alger Small Cap Focus Fund” fourth quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund underperformed the Russell 2000 Growth Index. The Energy and Communication Services sectors contributed to the fund’s relative performance in the quarter, while Consumer Discretionary […] |
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare SectorTo play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. |
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare ConferenceSAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 10:40 AM ET. A live and archived webcast of the fireside chat will be available via the |
TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current LevelsWith two full months of 2023 behind us, it’s hard to say just how this year is going to shape up. January saw a strong rally, while February was volatile and market analysts and economists are still debating where the long-term trends will head. But what can the retail investor do, while the professionals are debating? A turn to the data may yield some answers – and give clues toward compelling stocks. The Smart Score data tool from TipRanks is specially designed to cut through the fog of uncert |
RXDX Price Returns
| 1-mo | -9.07% |
| 3-mo | 1.17% |
| 6-mo | 88.60% |
| 1-year | 196.38% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 1.17% |
| 2022 | 178.20% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...